International Stem Cell Corporation (ISCO) Continues Upward Climb toward Changing the Face of Regenerative Medicine
A California-based biotechnology company, International Stem Cell Corporation (OTCQB: ISCO) focuses its energies on developing restorative medicine using stem cell technology. Its innovative parthenogenesis technology uses human stem cells derived from unfertilized oocytes (eggs), which helps the company avoid any ethical issues involving the destruction of viable human embryos. ISCO also produces and markets cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology. For even more revenue, the company’s other subsidiary, Lifeline Skin Care, markets and sells a skin care line that promises rejuvenation and beauty. In December, Lifeline Skin Care launched its Molecular Renewal…